Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting®

SAN DIEGO–(BUSINESS WIRE)– #AASLD22–Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), will present data from the completed Phase 1 healthy volunteer clinical trial for its lead candidate, OCE-205, at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 4-8, 2022, in Washington, DC. “With its unique profile as a mixed a
Click here to view original post